Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 46 of 46

Filter Applied: adverse drug reaction (Click to remove)

Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994

New-Onset Diplopia and Headache in a Patient with Metastatic Breast Cancer
Neurol 100:927-931, Rizzo,S.A.,et al, 2023

Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects
JENDSO 6:1-7, Hamidi, S.,et al, 2022

Atypical Posterior Reversible Encephalopathy Syndrome Associated with Lenvatinib Therapy in a Patient with Metastatic Thyroid-Cancer
Cancer Reports doi:10.1002/cnr2.1605, Abhishek, M.,et al, 2022

Sweet Syndrome
Stat Pearls www.ncbi.nlm.gov, Sept, Goyal,V.P. & Holmes,H, 2022

Encephalitis Induced by Immune Checkpoint Inhibitors
JAMA Neurol 78:864-873, Velasco, R.,et al, 2021

Autoimmune Encephalitis Related to Cancer Treatment with Immune Checkpoint Inhibitors
Neurol 97:e191-e202, Nersesjan, V.,et al, 2021

Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020

Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020

Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019

Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018

Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018

Immune Checkpoint Inhibitor-Related Myositis and Myocarditis in Patients with Cancer
Neurol 91:e985-e994, Touat, M.,et al, 2018

Nivolumab-Induced Autoimmune Encephalitis in Two Patients with Lung Adenocarcinoma
Case Rep Neurol Med 2018;doi:10.1155/2018/2548528, Shah, S.,et al, 2018

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017

Cytotoxic Lesions of the Corpus Callosum That Show Restricted Diffusion: Mechanisms, Causes, and Manifestations
RadioGraphics 37:562-576, Starkey, J.,et al, 2017

Malignancies after Mitoxantrone for Multiple Sclerosis
Neurol 86:2203-2207, Buttmann, M.,et al, 2016

Acute Demyelinating Polyneuropathy Caused by Nivolumab in a Man with Metastatic Non-Small Cell Lung Cancer
J Gerontol Geriatr Res 5:3, Sabeeh-Ur-Rehman, B. & Bhaumik, S., 2016

Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016

Utility of an Immunotherapy Trial in Evaluating Patients with Presumed Autoimmune Epilepsy
Neurol 82:1578-1586, Toledano, M.,et al, 2014

Erythromelalgia? A Clinical Study of People Who Experience Red, Hot, Painful Feet in the Community
Int J Vasc Med ID=864961, Friberg, D.,et al, 2013

Neurological Immune-Related Adverse Events of Ipilimumab
Pract Neurol 13:278-280, Bot, I.,et al, 2013

Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012

Spectrum of Neurologic Complications in Chronic Lymphocytic Leukemia
Clin Lymphoma Myeloma Leuk 12:164-179, Lopes da Silva, R., 2012

An Effective Immunotherapy Regimen for VGKC Antibody-Positive Limbic Encephalitis
JNNP 81:1167-1169, Wong,S.H.,et al, 2010

Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009

Risk Factors of Cerebral Vein and Sinus Thrombosis
Front Neurol Neurosci 23:23-54, de Freitas, G.R. & Bogousslavsky, J., 2008

Statin-Associated Myasthenia Gravis
Medicine 85:82-85, Purvin,V.,et al, 2006

Hyponatremia in Neurologic Patients: Consequences and Approaches to Treatment
The Neurologist 12:117-126, Diringer,M.N. &Zazulia,A., 2006

Tamoxifen:A New Risk Factor for Cerebral Sinus Thrombosis
Neurol 62:334-335, Masjuanh,J.,et al, 2004

Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004

Risk of Ischemic Stroke with Tamoxifen Treatment for Breast Cancer
Neurol 63:1230-1233, Bushnell,C.D. &Goldstein,L.B., 2004

Intrathecal Baclofen for Stiff-Person Syndrome: Life-Threatening Intermittent Catheter Leakage
Neurol 60:1976-1978, Bardutzky,J.,et al, 2003

Cerebral Sinus Thrombosis with Tamoxifen
Neurol 56:1113-1114, Finelli,P.F. & Schauer,P.K., 2001

Retrospective Analysis of the Use of Cyclosporine in Myasthenia Gravis
Neurol 55:448-450, Ciafaloni,E. et al, 2000

Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999

Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999

Clinicopath Conf,Multifocal Inflammatory Leukoencephalopathy Related to Combination Chemo with Fluorouracil/levamisole
NEJM 341:512-519, Case 24-1999, 1999

Intravenous Immunoglobulin in the Treatment of Autoimmune Neuromuscular Diseases:Present Status and Practical Therapeutic Guidelines
Muscle & Nerve 22:1479-1497, Dalakas,M.C., 1999

Medical Causes of Seizures
Lancet 352:383-390, Delanty,N.,et al, 1998

Drugs and Myasthenia Gravis, An Update
Arch Int Med 157:399-408, Wittbrodt,E.T., 1997

Opsoclonus
Semin Neurol 16:21-26, Averbuch-Heller,L.&Remler,B., 1996

Occurrence of Different Cancers in Patients with Parkinson's Disease
BMJ 310:1500-1501, Moller,H.,et al, 1995

Adverse Drug Effects on Neuromuscular Transmission
Semin Neurol 10:89-102, Howard,J.F., 1990

Hypoglycemia:Fact or Fiction
Mayo Clin Proc 60:844-850, Nelson,R.L., 1985



Showing articles 0 to 46 of 46